AbbVie Q2 Beat Overshadowed by EPS Cut for Apogee Deal; Shares Dip 4%

What happened

AbbVie reported robust second-quarter results and raised its revenue guidance, driven by continued momentum in key immunology drugs Skyrizi and Rinvoq. However, the company cut its 2026 earnings-per-share outlook to account for the recently announced Apogee Therapeutics acquisition, signaling near-term dilution. The stock fell roughly 4% as the EPS reduction weighed on sentiment, despite the top-line beat. The deal, which adds inflammatory disease pipeline assets, aligns with AbbVie’s need to diversify beyond its two-product concentration but carries execution and integration risk. The market’s reaction reflects investor concerns about the price paid and the temporary drag on profitability.

Implication

If the Apogee deal delivers on pipeline milestones, it could reduce long-term concentration risk, but the near-term dilution and execution uncertainty keep the stock in a wait-and-watch zone until the dust settles and 2026 immunology targets are confirmed.

Thesis delta

The Apogee acquisition introduces a new variable that modestly shifts the thesis: near-term earnings are now lower, but the deal could add a third growth leg beyond immunology over time. However, the core WAIT rating is unchanged, as the company must still prove it can sustain the $34.5B immunology framework while absorbing the deal’s costs. Clarity on the deal’s accretion timeline and continued strong quarterly results are needed to upgrade.